Call to Action: Comment on M4Q(R2)
Reading M4Q(R2) Is Exhausting. That is Exactly Why You Should Comment.
Initially published February 20, 2026
The draft revision of ICH M4Q(R2) is now open for comment and adopted into the FDA’s docket, and you, yes you, must make some time to read and comment on it.
Most people encountering the FDA’s draft guidance for The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality M4Q(R2) have the same response: a sigh, a scroll, and a quiet decision to come back to it later when they have time or worse, after it is already in place and you’re having to play catch up for these new requirements in which you did not provide your experience to shape.
The new draft is not reckless. It is not radical. It is not even wrong in any obvious, satisfying way, but it is fairly obtuse, harder to interpret, and alarmingly easy to misapply, with some updates to practices that should get your attention.
The comment window, however, will close whether industry engages or not on 03/23/2026.
If this guidance becomes final exactly as written, its implications will be discovered during a submission review rather than now during the comment window.
What the Draft Is Trying to Do
At its core, M4Q(R2) is an attempt to modernize the way Module 3 – Quality is structured, navigated, and reviewed.
On its surface, some modernizations are reasonable. Anyone who has tried to reconcile legacy CTD expectations with modern development programs understands the strain.
The draft makes a visible effort to:
Improve internal consistency across Quality sections
Attempt to clarify what information belongs in which section
Reduce redundancy that has crept in over years of regional interpretation, and
Improve and align content expectations with current ICH guidance
From a regulator’s perspective, this makes sense. Cleaner submissions mean cleaner reviews. Fewer interpretive leaps. Fewer circular questions.
No argument there. However, it is plausible that, alongside eCTD 4.0, there is a shift from narrative documents to structured digital data that the Agency can mine with artificial intelligence.
Where Pain Points Appear
The problem is not the goal. It is the structural shift and what that shift actually means in practice, not just for traditional products, but for novel delivery systems and cutting-edge technologies.
M4Q(R2) reads less like a restructuring guide and more like a document written by people who already know where everything lives in the dossier. It assumes a level of conceptual tidiness that does not exist in real programs with real histories, real constraints, and real regulatory baggage.
That is often not how submissions are actually assembled.
Most Module 3s are not written from scratch. Many are assembled, inherited, remediated, flipped, justified, and defended over time. Content exists because it already survived review once, not because it fits neatly into a revised outline.
This draft underestimates how destabilizing “clarification” can be when it collides with active development programs and late-stage filings. And that destabilization is not theoretical. It is structural.
What That “Clarification” Looks Like in Practice
The structural impacts to a submission for the latest version (R2) are outlined in Table 1.
Section titles are not cosmetic. In regulatory practice, headings define scope. When section names change, the boundaries of expectation move with them. Every SOP, cross-reference, publishing template, and historical submission indexed under the R1 hierarchy must be reconciled against the R2 framework.
R1 told sponsors where to place information and what to document. R2 evaluates how well that information integrates across the lifecycle and control architecture.
That is a shift in evaluative posture. Under R1, compliance was satisfied by documenting the science in the prescribed location. Under R2, the same content is judged for cross-sectional coherence.
The science does not change. The expectations for the sponsor do.
The Ambiguity Tax
One of the recurring frustrations in M4Q(R2) is ambiguity of expectation. But that ambiguity is now grounded in structural delta, not tone.
Under R1:
Manufacturing Process Development required documentation of changes.
Pharmaceutical Development was explicitly distinguished from routine controls
Analytical validation was structurally confined.
Stability reporting was segmented into summary, commitment, and data.
Under R2:
Development becomes lifecycle justification.
Validation becomes cross-sectional coherence.
Stability becomes lifecycle management evidence.
So, the real questions become:
Are sponsors being asked to relocate content, or reframe it?
Are the Regulators preserving structure, or redefining obligation?
Are these edits structural or substantive?
What is the cost impact estimate to the industry?
Those questions are not academic. They translate directly into rework, risk, and inspection posture, and frankly, time. Time most development teams do not have.
When guidance fails to clearly distinguish between preference and expectation, sponsors are left guessing, often to the detriment of their timelines. Guessing is expensive. Guessing is also how you end up defending decisions you did not realize you were making, or worse, having to live with them for the lifetime of the product.
An additional concern, if the FDA and ICH don’t provide new templates, sponsors will now have to contend with global implementation. Will sponsors need to do one sort of eCTD for FDA but maintain a different standard for other markets? What is the impact of maintaining multiple systems on sponsors who already bear the burden of compliance?
Why This Draft Needs Industry Feedback
Consider a sponsor with a late-stage BLA originally structured under M4Q(R1).
The Manufacturing Process Development section, 3.2.S.2.6, contains a careful history of process evolution. Comparability assessments are documented. Validation data are cross-referenced. The file survived review. It survived inspection.
Then, M4Q(R2) is adopted.
During a post-approval supplement, the sponsor restructures the section to align with the new lifecycle framing. Development history is redistributed. Control strategy language is strengthened. Cross-references shift.
An IR arrives.
The reviewer asks why certain comparability discussions previously located in 3.2.S.2.6 are no longer presented in the same way. The reviewer asks whether the restructuring reflects a substantive change in process understanding. The reviewer asks whether lifecycle alignment was previously incomplete.
Nothing about the science has changed. But the narrative moved.
Now the sponsor must defend not the process or the data, but the structure of the dossier. That defense can take months.
Not because the product is unsafe. Not because the validation failed.
But because headings changed. And once that exchange is entered into the review record, it follows the product for the rest of its lifecycle.
That is what guessing costs. This is not resistance to oversight. It is a request for operational clarity.
Regulators review submissions. Industry builds them. Those are related activities, but not identical ones. And industry is left holding the bag here for the dollars and minutes necessary to comply.
M4Q(R2) in its current form should not become final without grounded, specific feedback from people who:
Authors and Reviewers of Module 3 sections
Perform data verification
Defend legacy decisions during review
Remediate after questions come back
That’s basically all of us. SMEs, Reg affairs, and QA, we all need to get around a table and read this and make sure our concerns are on record.
A final document will codify a theory of work that may not quite match reality.
That helps no one. Least of all the reviewers who will have to enforce it. This fact, above all, is antithetical to the stated goal of improving the submissions.
The Implementation Question
This draft does not clearly state:
Whether M4Q(R2) applies only to new marketing applications
Whether supplements must conform immediately upon adoption
Whether ongoing BLAs and NDAs must restructure Module 3 content
Whether a transition period will be granted
In the absence of explicit transition language, sponsors must assume the most conservative interpretation: immediate applicability.
R1 formalized section numbering and hierarchy for harmonized eCTD use. Entire submission infrastructures (publishing software, RIM systems, SOP cross-references, regulatory templates) are built on that structure.
If R2 alters structural framing without explicit implementation guidance, those systems must be updated.
Restructuring Module 3 is not an editorial exercise. It requires:
Re-indexing submission libraries
Updating publishing configurations
Revising internal templates
Retraining regulatory staff
In many organizations, it also requires validated system requalification and vendor reconfiguration.
The draft does not address that burden. The comment deadline, however, is explicit.
What Useful Comments Actually Look Like
We must not make comments like: “Please clarify.”
Specific examples must be cited. Concrete commentary will create better guidance for all of us.
Like this:
In Section 3.2.S.2.6, clarify whether lifecycle control alignment is now an explicit expectation beyond historical change documentation.
In 3.2.P.2, clarify whether the development narrative must now demonstrate cross-sectional control strategy coherence.
In 3.2.S.4.3 / 3.2.P.5.3, confirm whether analytical validation remains a structurally bounded obligation or is now subject to broader lifecycle integration.
Provide explicit implementation guidance on applicability to supplements, ongoing INDs, NDAs, BLAs, and approved applications.
Final Thought
M4Q(R2) is not a bad draft. It is unfinished, appears to be moving forward prematurely, and needs help from professionals like you.
It reflects a sincere attempt to improve clarity, consistency, and reviewability. It also reflects a distance from the day-to-day mechanics of assembling and maintaining a Quality dossier across a product lifecycle.
That gap is exactly what the comment period is for.
If reading this draft made you tired in a way that felt professionally specific, that is not a personal failing. It is a signal.
The comment window closes on 03/23/2026. That deadline does not move because we are all busy.
Once the guidance is finalized, interpretation will shift from theoretical to enforceable. The first wave of information requests will define how these structural expectations are applied. After that, precedent sets quickly.
If the people who recognize the structural shifts stay quiet now, the lifecycle framing, the integration expectations, and the implementation burdens will become fixed through enforcement rather than discussion.
Silence, in this case, will be interpreted as agreement with the structural and lifecycle expectations outlined above.
Comments